HUTCHMED (China) Limited (HCM)
USD 11.81
(-2.72%)
USD 11.81
(-2.72%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 50.25 Million USD | -11.35% |
| 2022 | 56.69 Million USD | 58.55% |
| 2021 | 35.75 Million USD | 80.89% |
| 2020 | 19.76 Million USD | 21.95% |
| 2019 | 16.2 Million USD | 31.68% |
| 2018 | 12.3 Million USD | 4.41% |
| 2017 | 11.78 Million USD | -8.06% |
| 2016 | 12.82 Million USD | 34.19% |
| 2015 | 9.55 Million USD | 116.91% |
| 2014 | 4.4 Million USD | 210.21% |
| 2013 | 1.42 Million USD | -94.39% |
| 2012 | 25.31 Million USD | -11.84% |
| 2011 | 28.71 Million USD | 7.84% |
| 2010 | 26.63 Million USD | 52.39% |
| 2009 | 17.47 Million USD | 18.76% |
| 2008 | 14.71 Million USD | 25.52% |
| 2007 | 11.72 Million USD | 23.52% |
| 2006 | 9.49 Million USD | 9.37% |
| 2005 | 8.67 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 46.44 Million USD | -7.59% |
| 2024 Q2 | 46.44 Million USD | 0.0% |
| 2023 Q3 | 50.25 Million USD | -6.71% |
| 2023 FY | 50.25 Million USD | -11.35% |
| 2023 Q1 | 53.87 Million USD | -4.97% |
| 2023 Q2 | 53.87 Million USD | 0.0% |
| 2023 Q4 | 50.25 Million USD | 0.0% |
| 2022 Q3 | 56.69 Million USD | 23.44% |
| 2022 Q1 | 45.92 Million USD | 28.44% |
| 2022 Q4 | 56.69 Million USD | 0.0% |
| 2022 FY | 56.69 Million USD | 58.55% |
| 2022 Q2 | 45.92 Million USD | 0.0% |
| 2021 Q2 | 25.5 Million USD | 29.09% |
| 2021 FY | 35.75 Million USD | 80.89% |
| 2021 Q1 | 19.75 Million USD | -0.05% |
| 2021 Q4 | 35.75 Million USD | 0.0% |
| 2021 Q3 | 35.75 Million USD | 40.19% |
| 2020 Q4 | 19.76 Million USD | 0.0% |
| 2020 Q2 | 15.26 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 FY | 19.76 Million USD | 21.95% |
| 2020 Q3 | 19.76 Million USD | 29.51% |
| 2019 Q2 | 14.22 Million USD | -19.24% |
| 2019 Q4 | 16.2 Million USD | 3.55% |
| 2019 FY | 16.2 Million USD | 31.68% |
| 2019 Q1 | 17.61 Million USD | 43.08% |
| 2019 Q3 | 15.65 Million USD | 10.05% |
| 2018 FY | 12.3 Million USD | 4.41% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q4 | 12.3 Million USD | 0.0% |
| 2018 Q2 | 9.78 Million USD | 0.0% |
| 2017 Q2 | 10.68 Million USD | 0.0% |
| 2017 Q3 | 11.78 Million USD | 10.31% |
| 2017 Q1 | 10.68 Million USD | -16.65% |
| 2017 FY | 11.78 Million USD | -8.06% |
| 2017 Q4 | 11.78 Million USD | 0.0% |
| 2016 Q4 | 12.82 Million USD | 0.0% |
| 2016 FY | 12.82 Million USD | 34.19% |
| 2016 Q3 | 12.82 Million USD | 61.83% |
| 2016 Q2 | 7.92 Million USD | 0.0% |
| 2016 Q1 | 7.92 Million USD | -17.08% |
| 2015 Q1 | 7 Million USD | 59.11% |
| 2015 Q3 | 10.08 Million USD | 43.87% |
| 2015 Q4 | 9.55 Million USD | -5.25% |
| 2015 FY | 9.55 Million USD | 116.91% |
| 2015 Q2 | 7 Million USD | 0.0% |
| 2014 Q1 | 4.09 Million USD | 188.52% |
| 2014 FY | 4.4 Million USD | 210.21% |
| 2014 Q2 | 4.09 Million USD | 0.0% |
| 2014 Q4 | 4.4 Million USD | 0.0% |
| 2013 Q1 | 1.19 Million USD | -95.28% |
| 2013 FY | 1.42 Million USD | -94.39% |
| 2013 Q3 | 1.42 Million USD | 18.73% |
| 2013 Q2 | 1.19 Million USD | 0.0% |
| 2013 Q4 | 1.42 Million USD | 0.0% |
| 2012 Q3 | 1.59 Million USD | -92.62% |
| 2012 Q2 | 21.55 Million USD | 0.0% |
| 2012 FY | 25.31 Million USD | -11.84% |
| 2012 Q4 | 25.31 Million USD | 1492.33% |
| 2011 FY | 28.71 Million USD | 7.84% |
| 2011 Q4 | 28.71 Million USD | 0.0% |
| 2010 Q2 | 22.77 Million USD | 0.0% |
| 2010 Q4 | 26.63 Million USD | 0.0% |
| 2010 FY | 26.63 Million USD | 52.39% |
| 2009 FY | 17.47 Million USD | 18.76% |
| 2009 Q4 | 17.47 Million USD | 0.0% |
| 2008 FY | 14.71 Million USD | 25.52% |
| 2007 FY | 11.72 Million USD | 23.52% |
| 2006 FY | 9.49 Million USD | 9.37% |
| 2005 FY | 8.67 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Journey Medical Corporation | 10.2 Million USD | -392.436% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 54.802% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -642.473% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 51.838% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -776.376% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -776.376% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Safety Shot Inc | 1.86 Million USD | -2588.101% |
| Alpha Teknova, Inc. | 11.59 Million USD | -333.483% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -55.444% |
| Bright Green Corporation | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 5.69% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 23.414% |
| Cosmos Health Inc. | 4.78 Million USD | -949.435% |
| PainReform Ltd. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -6106.553% |
| Embecta Corp. | 152.1 Million USD | 66.957% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -331.51% |
| Procaps Group, S.A. | 96.83 Million USD | 48.098% |
| Theratechnologies Inc. | 6.06 Million USD | -728.52% |
| Harrow Health, Inc. | 10.86 Million USD | -362.483% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -1748.4% |
| Biofrontera Inc. | 10.9 Million USD | -360.744% |
| DURECT Corporation | 2.21 Million USD | -2164.894% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 35.074% |
| Cronos Group Inc. | 30.33 Million USD | -65.655% |
| OptiNose, Inc. | 8.05 Million USD | -524.168% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -5025799900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -781.869% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -77.886% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -1777.322% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -990.346% |
| Radius Health, Inc. | 278.64 Million USD | 81.963% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -1403.261% |
| ProPhase Labs, Inc. | 3.84 Million USD | -1208.461% |
| Phibro Animal Health Corporation | 265.91 Million USD | 81.1% |
| Procaps Group S.A. | 96.83 Million USD | 48.098% |
| Alvotech | 74.43 Million USD | 32.479% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 98.552% |
| Rockwell Medical, Inc. | 5.87 Million USD | -756.038% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -297.831% |
| SIGA Technologies, Inc. | 64.21 Million USD | 21.739% |
| Tilray Brands, Inc. | 252.08 Million USD | 80.063% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | -25.711% |
| Shineco, Inc. | 1.58 Million USD | -3063.815% |
| PetIQ, Inc. | 159.3 Million USD | 68.453% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 32996.098% |
| Incannex Healthcare Limited | -10.01 Million USD | 601.827% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -31.222% |
| Alimera Sciences, Inc. | 1.87 Million USD | -2574.721% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | -33.36% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -3020.857% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -1021.08% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -19659.231% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -384.181% |
| Hempacco Co., Inc. | 2.54 Million USD | -1876.616% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 32.479% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | -5.155% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 21.507% |
| Currenc Group, Inc. | 732.91 Thousand USD | -6757.313% |
| Kamada Ltd. | 87.74 Million USD | 42.724% |
| Indivior PLC | 141.79 Million USD | 64.557% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -10330.433% |
| Flora Growth Corp. | 8.5 Million USD | -490.715% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -19659.231% |
| Evolus, Inc. | 10.99 Million USD | -356.974% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 52.512% |
| Akanda Corp. | 1.28 Million USD | -3805.372% |